Abstract The discovery of bioactive small molecules is dominated by iterative design-make-purify-test cycles focused on specific protein targets. In contrast, phenotype-driven discovery can yield bioactive molecules with unexpected mechanisms of action, and open paths to first-in-class drugs. Here, we present a fully closed-loop, algorithm-driven workflow for phenotypic-driven molecular discovery. Initially, a large virtual reaction space is constructed from pairs of potential substrates and co-substrates. Batches of reactions are then algorithmically-designed and automatically executed, and the products screened in a phenotypic assay; based on observed hits, the algorithm then directs subsequent round(s) of discovery and optimisation until a user-defined end-point is reached. The approach was exemplified using Rh-catalysed annulations of hydoxamate esters with alkene/alkyne co-substrates, coupled with the cell painting assay, and enabled the discovery and structural evolution of a series of tubulin modulators. Because the workflow is agnostic to both the chemistry and the assay modality, the approach may be generalisable for the automated function-directed exploration of synthetically-accessible chemical space. The approach has the potential to accelerate the discovery of chemical probes and to unlock opportunities for drug discovery.
Piticari et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: